Home > Haematology > EHA 2021 > Thrombotic and Thrombocytopenic Disorders including COVID-19 related > Physiopathology of coagulopathy in haematological malignancies and COVID-19

Physiopathology of coagulopathy in haematological malignancies and COVID-19

Presented By
Prof. Marcel Levi, Amsterdam University Medical Centre, the Netherlands
Conference
EHA 2021
Coagulopathies in critically ill patients display similar clinical manifestations but have distinctly different underlying pathophysiologies. Prof. Marcel Levi (Chair of the Dutch Research Council; Amsterdam University Medical Centre, the Netherlands) presented the pathophysiology of coagulopathies in patients with cancer and COVID-19 [1]. Excessive blood loss during disseminated intravascular coagulation (DIC) is much more common in cancer patients (10–20%) than in DIC associated with other conditions (1–5%) and associated with higher mortality. The most important contributing cause for coagulopathies in cancer patients is tissue factor (TF) in TF-bearing microparticles of tumour cells. Furthermore, there is direct platelet-cancer interaction as well as thrombotic complications that arise due to anticancer drugs [2]. Coagulopathy in COVID-19 is difficult to classify due to its overlapping features with DIC, thrombotic microangiopathy, catastrophic...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on